Skip to main content
Natasha Halasa on Muck Rack

Natasha Halasa

As seen in: Center for Disease Control and Prevention, Nature, Wiley Online Library, JAMA (The Journal of the American Medical Association), The New England Journal of Medicine, Healio Pulmonology, Texas Medical Center, The Journal of Pediatrics, The Journal of Allergy & Clinical Immunology, Contemporary Pediatrics and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Natasha

Contact Natasha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Antiviral CD4 + T and myeloid cell responses to influenza vaccines are attenuated in older adults

|
By Jared Oakes, Joshua Simmons, Cindy Hager-Nochowicz, Leslie Kirk, Natasha Halasa, H. Keipp Talbot, Samuel S Bailin, Jessica L Castilho, Spyros A. Kalams, Joan Eason
| Nature Verified
Abstract Recent influenza vaccine formulations have improved the magnitude of B-cell antibody responses in older adults; however, older adults remain significantly at risk for severe influenza-related illness. Although antibodies are an important metric of vaccine effectiveness, they only represent one aspect of the immune response.
Open in Who Shared Issue with article?

Comparing procalcitonin and C-reactive protein levels in very low birth weight infants with sepsis

|
By Tess Stopczynski, Ritu Banerjee, Natasha Halasa, Scott Guthrie, Gregory Ayers, Joern-Hendrik Weitkamp, Samantha Eschborn, Dorianna C. Dobson, Alexander G. Agthe
| Nature Verified
Abstract While C-reactive protein (CRP) is a commonly used sepsis biomarker in neonates, studies in older patients propose procalcitonin (PCT) as potentially superior due to earlier rise in response to bacterial infection and shorter half-life. We conducted a prospective cohort study of VLBW infants undergoing sepsis evaluations at a level IV neonatal intensive care unit (NICU) and combined the analysis with a retrospective data review from a different level III NICU.
Open in Who Shared Issue with article?

Establishing Permanence, Not Patchwork: Sustaining Coordinated Research Networks for Immunocompromised Populations

|
By Haya Hayek, Natasha Halasa, Joshua A. Hill
| Wiley Online Library Verified
No abstract is available for this article. Conflicts of Interest H.H has no conflict of interest to disclose. N.B.H has received past research support from Merck, and current research support from Sanofi. J.A.H. has received research support paid to his institution from GeoVax, Karius, Sanofi, Takeda, and Gilead and has consulted for Allovir, Symbol, CSL Behring, Gevax, Karius, Moderna, Sanofi, Takeda, and Gilead.
Open in Who Shared Issue with article?
See all 14 licensed articles (33 Total)